Skip to Content

Medications for Dravet Syndrome

Other names: Severe Myoclonic Epilepsy of Infancy; SMEI

About Dravet Syndrome: 

Dravet syndrome is a rare type of epilepsy that begins in the first year of life in an otherwise healthy child. A syndrome is a combination of specific signs and symptoms that when occur together are diagnosed as a medical condition. 

Dravet syndrome patients have a particular type and pattern of epileptic seizures and as the syndrome progresses other issues become apparent including developmental delay or regression, sleep disturbance issues, behaviour problems and mobility concerns such as unsteady gait. The first seizure usually occurs in the first 12 months of life and this often occurs while the child has fever due to illness or vaccination. Following the first seizure more seizures follow with increasing severity, changes in seizure type and often the seizures become unpredictable, frequent and difficult to control.

The seizures often start out as jerky movements (clonic seizures), that are prolonged and more likely to affect one side of the body.  As the syndrome progresses the seizures types can include myoclonic seizures (affecting whole or half of the body), atypical absence seizures, focal seizures, serial seizures or status epilepticus.  Dravet syndrome patients are more prone status epilepticus, which is when there is a long lasting seizure or when seizures occur close together without recovery between them.  With Dravet syndrome there is an increased risk of sudden unexplained death in epilepsy (SUDEP) compared to other types of epilepsy.


Most patients with Dravet syndrome have a change or mutation in the SCN1a gene which causes a faulty protein to be made. This faulty protein reduces the brain’s ability to control electrical messages within the brain and causes seizures.

Drugs Used to Treat Dravet Syndrome

The following list of medications are in some way related to, or used in the treatment of this condition.

Drug name Rx / OTC Pregnancy CSA Alcohol Reviews Rating Popularity
Diacomit N X Add review
0.0

Generic name: stiripentol systemic

Drug class: gamma-aminobutyric acid reuptake inhibitors

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

Epidiolex N X Add review
0.0

Generic name: cannabidiol systemic

Drug class: miscellaneous anticonvulsants

For consumers: dosage, interactions, side effects

For professionals: AHFS DI Monograph, Prescribing Information

cannabidiol N X Add review
0.0

Generic name: cannabidiol systemic

Brand name:  Epidiolex

Drug class: miscellaneous anticonvulsants

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph, Natural Product Monographs

stiripentol N X Add review
0.0

Generic name: stiripentol systemic

Brand name:  Diacomit

Drug class: gamma-aminobutyric acid reuptake inhibitors

For consumers: dosage, interactions,

For professionals: A-Z Drug Facts, AHFS DI Monograph

Fintepla C 4 X Add review
0.0

Generic name: fenfluramine systemic

Drug class: CNS stimulants

For consumers: interactions,

Legend

Rx Prescription Only
OTC Over the Counter
Rx/OTC Prescription or Over the Counter
Off Label This medication may not be approved by the FDA for the treatment of this condition.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Browse Treatment Options

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.